Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2017

  • ID: 4200775
  • Drug Pipelines
  • 95 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 2-BBB Medicines BV
  • Biogen Inc
  • Bionure Farma SL
  • Clene Nanomedicine Inc
  • HanAll Biopharma Co Ltd
  • Karus Therapeutics Ltd
  • MORE
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2017, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person’s immune system (the body’s natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 3, 4 and 8 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 2-BBB Medicines BV
  • Biogen Inc
  • Bionure Farma SL
  • Clene Nanomedicine Inc
  • HanAll Biopharma Co Ltd
  • Karus Therapeutics Ltd
  • MORE
Introduction

Report Coverage

Neuromyelitis Optica (Devic’s Syndrome) - Overview

Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development

2-BBB Medicines BV

Alexion Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Biogen Inc

Bionure Farma SL

Chugai Pharmaceutical Co Ltd

Clene Nanomedicine Inc

HanAll Biopharma Co Ltd

Karus Therapeutics Ltd

LFB SA

Marathon Pharmaceuticals LLC

MedImmune LLC

Opexa Therapeutics Inc

Shire Plc

Neuromyelitis Optica (Devic’s Syndrome) - Drug Profiles

2B-3201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANV-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APL-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BN-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cladribine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNMAU-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-15107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inebilizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KA-1463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPX-212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SA-237 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-623 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Neuromyelitis Optica - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ublituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects

Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones

Featured News & Press Releases

Sep 16, 2016: TG Therapeutics Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Aug 31, 2016: TG Therapeutics Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Aug 26, 2016: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder

Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)

Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program

Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol

May 08, 2015: Initiation Of Phase I Clinical Program

Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting

Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned

Feb 25, 2015: HanAll BioPharma Receives a Grant for HL161 Auto-Immune Project from Korean Drug Development Fund

Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica

Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program

Aug 27, 2014: Clene Files Investigational New Drug Application With FDA

Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis

Apr 01, 2014: Clene Nanomedicine Requests Pre-IND Meeting With FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by 2-BBB Medicines BV, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Apellis Pharmaceuticals Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Biogen Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bionure Farma SL, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Clene Nanomedicine Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Karus Therapeutics Ltd, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by LFB SA, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Marathon Pharmaceuticals LLC, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by MedImmune LLC, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Opexa Therapeutics Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Shire Plc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H1 2017

List of Figures:

Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 2-BBB Medicines BV
  • Alexion Pharmaceuticals Inc
  • Apellis Pharmaceuticals Inc
  • Biogen Inc
  • Bionure Farma SL
  • Chugai Pharmaceutical Co Ltd
  • Clene Nanomedicine Inc
  • HanAll Biopharma Co Ltd
  • Karus Therapeutics Ltd
  • LFB SA
  • Marathon Pharmaceuticals LLC
  • MedImmune LLC
  • Opexa Therapeutics Inc
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll